Clinical Trials Logo

Immune Thrombocytopenia clinical trials

View clinical trials related to Immune Thrombocytopenia.

Filter by:

NCT ID: NCT05369377 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib plus eltrombopag compared to eltrombopag monotherapy for the first-line treatment of adults with chronic immune thrombocytopenia (ITP).

NCT ID: NCT05369364 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

NCT ID: NCT05302024 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: March 22, 2022
Phase: Phase 2
Study type: Interventional

A phase 2, open-label, single-arm study to evaluate the efficacy and safety of iguratimod for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP)

NCT ID: NCT05124028 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

A Study of Orelabrutinib in Patients With ITP

Start date: December 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

NCT ID: NCT05020288 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

BTK participates in a variety of signal transduction of innate and adaptive immunity, and has an important role in cell proliferation, differentiation and apoptosis. The impact of BTK inhibitors on hematological malignancies and autoimmune diseases has been well studied. This project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of the selective BTK inhibitor Orelabrutinib in the management of refractory ITP.

NCT ID: NCT04618328 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

A Study of ATRA in the Treatment of ITP

Start date: November 2020
Phase: Phase 2
Study type: Interventional

An open-label, multicenter study to compare the efficacy and safety of ATRA for the treatment of adults with primary immune thrombocytopenia (ITP)

NCT ID: NCT04320225 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune Thrombocytopenia

Start date: October 1, 2020
Phase:
Study type: Observational

The project was undertaking by Qilu Hospital of Shandong University in China. The objective is to find out if there is a connection between vitamin D level and the efficacy of dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

NCT ID: NCT04311593 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura

Start date: May 2020
Phase:
Study type: Observational

In this study, we will focus on the independent prognostic relevance of the expressions of CD38, CD4, CD56, CD11b and CD19 markers in immune cells with platelet changes in patients with newly diagnosed and chronic ITP.

NCT ID: NCT04289207 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

In this study, we tried to demonstrate clinical benefit of additive danazol to romiplostim therapy in patients with eltrombopag-resistant immune thrombocytopenia

NCT ID: NCT04102033 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Eltrombopag in Chronic ITP

Start date: November 1, 2019
Phase: Phase 4
Study type: Interventional

This study aims to evaluate the efficacy of eltrombopag on the platelet count in pediatric patients with chronic immune thrombocytopenia.